Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 1c. Details of Included Studies—Articles With Information on Predictors of Response to Thalidomide Corresponding to Tables 11-14

First Author, Year

Treatment

N

Quality

Predictor

Predictors related to the potential mechanism of thalidomide action (Table 11)

Singhal, 1999 {Singhal, #592}

Thal only

84

5/5

BM Microvascular Density

Mileshkin, Prince, et al., 2003127

  75

4/6

Serum mucin-1 (sMUC-1)

Dmoszynska, 2002128

  30

3/5

Fibroblast Growth Factor (FGF)

Neben, Moehler, Egerer, et al., 200152

Thal only

54

3/6

Fibroblast Growth Factor (FGF)

Neben, Moehler, Kraemer, et al., 2001129

  51

3/6

Fibroblast Growth Factor (FGF)

Tosi, 2002 57

Thal only

65

2/5

Fibroblast Growth Factor (FGF)

Neben, Moehler, Kraemer, et al., 2001129

  51

3/6

Hepatocyte growth factor (HGF)

Dmoszynska, 2002128

  30

35

Interleukin-6 (IL-6)

Neben, Moehler, Kraemer, et al., 2001129

  51

3/6

Interleukin-6 (IL-6)

Thompson, 2003130

  38

1/5

Interleukin-6 (IL-6)

Dmoszynska, 2002128

  30

3/6

Tumor necrosis factor alpha (TNFα)

Neben, Moehler, Kraemer, et al., 2001129

  51

3/6

Tumor necrosis factor alpha (TNFα)

Thompson, 2003130

  38

1/5

Tumor necrosis factor alpha (TNFα)

Neben, Mytilineos, et al., 2002131

  81

3/6

TNFα polymorphisms at position -238 of the gene promoter

Neben, Mytilineos, et al., 2002131

  81

3/6

TNFα polymorphisms at position -308 of the gene promoter

*Jaksic, 2004 (ASH 2417)132

  16

*

t(4;14) positive multiple myeloma

Dmoszynska, 2002128

  30

3/5

Vascular Endothelial Growth Factor (VEGF)

Neben, Moehler, Egerer, et al., 200152

Thal only

54

3/6

Vascular Endothelial Growth Factor (VEGF)

Neben, Moehler, Kraemer, et al., 2001129

  51

3/6

Vascular Endothelial Growth Factor (VEGF)

Tosi, 2002 57

Thal only

65

2/5

Vascular Endothelial Growth Factor (VEGF)

Total # studies in category: 9
Total abstracts (*): 1

     

Total predictors in category studied: 10

Predictors related to patient demographic factors (Table 12)

Barlogie, 2002109

Thal + other

231

4/6

Age

Mileshkin, Biagi, et al., 200399

Thal + other

75

5/6

Age

Shaughnessy, 2003133

  231

2/6

Age

Yakoub-Agha, 200260

Thal only

83

6/6

Age

Dimopoulos, 200494

Thal + other

53

3/5

Gender

Dimopoulos, 200170

Thal + Dex

44

3/5

Performance status (ECOG)

Dimopoulos, 200494

Thal + other

53

3/5

Performance status (ECOG)

Singhal, 199935

Thal only

84

5/5

% of plasma cells in BM

Garcia-Sanz, 200495

Thal + other

66

4/5

Relapsed versus refractory disease

Yakoub-Agha, 200260

Thal only

83

6/6

Time from diagnosis to onset of Thal

Total # studies in category: 8
Total abstracts (*): 0

     

Total predictors in category studied: 6

Predictors related to clinical diagnostic test results (Table 13)

Barlogie, 200143

Thal only

169

4/6

Cytogenetics

Shaughnessy, 2003133

  231

2/6

Cytogenetics

Barlogie, 2002109

Thal + other

231

2/5

Chromosome 13 abnormality

Mileshkin, Biagi, et al., 200399

Thal + other

75

2/6

Chromosome 13 abnormality

Shaughnessy, 2003133

  231

2/6

Chromosome 13 abnormality

Singhal, 199935

Thal only

84

5/5

Chromosome 13 abnormality

*Attal, 2004 (ASH 535)108

Thal + other

580

*

Chromosome 13 abnormality

Dimopoulos, 200494

Thal + other

53

3/5

Albumin

Shaughnessy, 2003133

  231

2/6

Albumin

Singhal, 199935

Thal only

84

5/5

Albumin

Yakoub-Agha, 200260

Thal only

83

6/6

Albumin

Garcia-Sanz, 200495

Thal + other

66

4/5

Beta 2 microglobulin (B2M)

Mileshkin, Biagi, et al., 200399

Thal + other

75

5/6

Beta 2 microglobulin (B2M)

Neben, Moehler, Egerer, et al., 200152

Thal only

54

3/6

Beta 2 microglobulin (B2M)M

Shaughnessy, 2003133

  231

2/6

Beta 2 microglobulin (B2M)

Schutt, 200587

Thal + other

31

5/5

Beta 2 microglobulin (B2M)

*Attal, 2004 (ASH 535)108

Thal + other

580

*

Beta 2 microglobulin (B2M)

Dimopoulos, 200170

  44

3/5

Hemoglobin

Mileshkin, Biagi, et al., 200399

Thal + other

75

3/6

Hemoglobin

Neben, Moehler, Egerer, et al., 200152

  54

3/6

Hemoglobin

Garcia-Sanz, 200495

Thal + other

66

4/5

Platelets

Dimopoulos, 200170

Thal + Dex

44

3/5

Serum lactose dehydrogenase (LDH)

Dimopoulos, 200494

Thal + other

53

3/5

Serum lactose dehydrogenase (LDH)

Mileshkin, Biagi, et al., 200399

Thal + other

75

5/6

Serum lactose dehydrogenase (LDH)

Shaughnessy, 2003133

  231

2/6

Serum lactose dehydrogenase (LDH)

Singhal, 199935

Thal + other

84

5/5

Serum lactose dehydrogenase (LDH)

Shaughnessy, 2003133

  231

2/6

C Reactive Protein

Singhal, 199935

Thal + other

84

5/5

C Reactive Protein

Yakoub-Agha, 200260

Thal only

83

6/6

IgA Isotype

Dimopoulos, 200170

Thal + Dex

44

3/5

Light chain type

Barlogie, 200143

Thal only

169

4/6

Plasma cell labeling index

Singhal, 199935

Thal only

84

5/5

Plasma cell labeling index

Total # studies in category: 12
Total abstracts (*): 1

     

Total predictors in category studied: 11

Predictors related to Clinical Response to Thalidomide

Neben, Moehler, et al., 2002134

  83

4/6

Cumulative 3-mo Thal dosage

Yakoub-Agha, 200260

Thal only

83

6/6

Cumulative 3-month Thal dosage

Schey, 200355

Thal only

69

4/5

Change in paraprotein levels

Singhal, 199935

Thal only

84

5/5

Relationship between paraprotein response and BM response

Total # studies in category: 4
Total abstracts (*): 0

     

Total predictors in category studied: 3

Abbreviations: B2M=beta 2 microglobulin, BM=bone marrow, Dex=dexamethasone, ECOG=Eastern Cooperative Oncology Group, FGF=Fibroblast Growth Factor, HGF=hepatocyte growth factor, IFN=interferon, PS=performance status, sMUC-1=serum mucin-1, Thal=Thalidomide, TNF=tumor necrosis factor, VEGF=Vascular Endothelial Growth Factor.

Return to Document

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care